A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

Clinical trial NCT05108922 · COMPLETED

Trial details

NCT number: NCT05108922
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Mild Cognitive Impairment (MCI)Alzheimer Disease

Start date: 2021-11-16
Primary completion: 2022-09-09
Enrollment: 148

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.